Stimuli-Responsive Cell-Mimetic Vesicles for Advanced Pharmaceutical Systems Authors: Hyewon Jeon, Jaehyun Cheong, Jain Koo, Chaehyeon Ha, Hyunjung Cho, Seunghee Cheon, Kyung Taek Oh Published: 2026 ABSTRACT AbstractVesicles have emerged as versatile drug delivery platforms owing to their ability to co-encapsulate both hydrophilic and hydrophobic cargos, enabling combination therapies and multifunctional treatment strategies. To overcome the limitations of conventional carriers, such as insufficient accumulation at target sites and nonspecific biodistribution, extensive efforts have focused on introducing stimuli-responsive functionalities that provide spatiotemporally controlled drug release, enhanced targeting specificity, and reduced systemic toxicity. More recently, vesicle-based systems have evolved beyond passive delivery vehicles into artificial cell-like platforms capable of in situ biosynthesis, stimulus-regulated therapeutic responses, and communication with living cells. Although substantial progress has been made in vesicle engineering, existing studies have largely addressed conventional delivery systems, stimuli-responsive vesicles, and artificial cells as distinct research domains. Consequently, a comprehensive perspective describing their functional evolution toward sophisticated therapeutic systems remains lacking. This review addresses this gap by integrating recent advances across these areas to examine how vesicular platforms have progressed from drug carriers to adaptive cell-mimetic therapeutic systems. Special emphasis is placed on structural design principles that enable functional diversification, the incorporation of targeting and stimuli-responsive elements, and the emergence of artificial cell-like systems capable of localized biomolecule production and biological interaction. In addition, key challenges, including the balance between membrane stability and responsiveness, efficient molecular exchange across vesicular membranes, and the integration of multiple biological functions within a single platform, are discussed. Collectively, these advances highlight the transformation of vesicle-based systems from passive nanocarriers into programmable therapeutic entities and provide a framework for the rational design of next-generation nanomedicines. Introduction Vesicular carriers have been extensively investigated for cancer therapy owing to their excellent biocompatibility and capacity to encapsulate a broad range of therapeutic agents. These carriers possess bilayer membranes enclosing an aqueous core, enabling efficient encapsulation and protection of therapeutic cargo from degradation and rapid systemic clearance.1,2 In contrast to polymeric micelles, vesicular carriers enable the simultaneous loading of both hydrophilic and hydrophobic agents, offering distinct advantages for combination therapy applications.3,4 In addition to cancer therapy, vesicular carriers have shown considerable promise in vaccine delivery, gene therapy, and protein-based therapeutics owing to their ability to protect sensitive biomacromolecules from degradation, improve their pharmacokinetic profiles, and facilitate controlled delivery to target tissues. Various vesicular carriers have been developed, including liposomes, polymersomes, hybrid lipopolymersomes, and exosomes. Liposomes are composed of phospholipid bilayers,5,6 whereas polymersomes are constructed from amphiphilic block copolymers and exhibit enhanced mechanical stability.7,8 Hybrid lipopolymersomes have been designed to integrate the complementary advantages of both liposomes and polymersomes. More recently, exosomes—naturally derived extracellular vesicles—have attracted attention as carriers owing to their potential for biological functionality and efficient cellular communication.9–11 However, conventional vesicular carriers have limitations, including nonspecific biodistribution, systemic toxicity, and reduced therapeutic efficacy caused by premature drug leakage and insufficient accumulation at target sites.12,13 To address these challenges, stimuli-responsive functionalization strategies have been explored to minimize off-target side effects and enhance therapeutic efficacy through targeted drug delivery.14–16 These strategies improve drug release in response to tumor-associated conditions, such as acidic pH, enzymatic activity, or externally applied triggers.17,18 Furthermore, incorporation of targeting ligands and functional additives into stimuli-responsive carriers can enhance therapeutic efficacy through synergistic mechanisms. Recently, vesicular carriers have evolved beyond simple delivery systems into complex, cell-like compartments capable of biomimetic and biochemical functions.19 In particular, vesicle-based artificial cells represent a paradigm shift from passive drug delivery systems to active therapeutic platforms, enabling in situ synthesis and controlled release of therapeutic biomolecules within the tumor microenvironment.20–23 These systems provide a fundamentally distinct approach by enabling localized production and immediate utilization of therapeutic agents that are otherwise challenging to deliver systemically.24,25 Accordingly, vesicular carriers are increasingly being developed as functionally active platforms that directly participate in therapeutic responses within the tumor microenvironment. To the best of our knowledge, previous studies have primarily addressed vesicular carriers, stimuli-responsive systems, and artificial cell-like platforms as separate research domains, highlighting the need for their integration within a unified framework of functional evolution. Therefore, this review first outlines the types and characteristics of vesicular carriers, as well as recent advances in stimuli-responsive strategies. Subsequently, we discuss their evolution into artificial cell-like platforms for enhanced therapeutic performance, highlighting representative studies and emerging design strategies for biomedical applications. Structural Features and Encapsulation Strategies of Vesicular Carriers Classification of Vesicular Carriers As shown in Figure 1, vesicular carriers possess a bilayer membrane structure enclosing an internal aqueous core, which is separated from the external environment. This architecture enables the co-encapsulation of hydrophilic cargos within the aqueous core and hydrophobic molecules within the membrane bilayer.2,4 Based on membrane composition, vesicular carriers are broadly classified into liposomes, polymersomes, hybrid lipopolymersomes, and exosomes, each exhibiting distinct physicochemical properties.26 Figure 1Schematic comparison of membrane bilayer structures of representative vesicular carriers. Created with BioRender.com. The bilayer membrane illustration was adapted from (Kim et al, 2022)27, MDPI, distributed under the Creative Commons Attribution (CC BY 4.0) license.A scientific schematic titled ′Vesicles′ features a top section with a circular bilayer vesicle diagram labeled ′Aqueous core′ and ′Hydrophobic membrane core.′ A box labeled ′Encapsulated cargo′ lists Peptides, siRNA, mRNA, Hydrophilic drugs and Hydrophobic drugs with icons. An inset micrograph shows vesicle outlines labeled ′Bilayer membrane.′ Below, a two by two grid compares vesicle types: Liposome with Phospholipid and Cholesterol; Polymersome with Block copolymer; Exosome with surface features like Tetraspanin, Integrin, PD-L1, MHC I, MHC II, Phospholipid; Hybrid lipopolymersome with Phospholipid, Block copolymer, Cholesterol.Labeled schematic titled Vesicles comparing 4 vesicle types and encapsulated cargo. Schematic comparison of membrane bilayer structures of representative vesicular carriers. Created with BioRender.com. The bilayer membrane illustration was adapted from (Kim et al, 2022)27, MDPI, distributed under the Creative Commons Attribution (CC BY 4.0) license. Liposomes Liposomes are composed of phospholipid bilayers that closely resemble cellular membranes, resulting in excellent biocompatibility, low immunogenicity, and efficient cellular uptake.28–30 Initially developed for hydrophilic drug delivery, liposomes can encapsulate hydrophilic agents in their aqueous core and hydrophobic compounds within the lipid bilayer.6 Since their discovery by Bangham in the 1960s, liposomes have been extensively used as vesicular carriers owing to their favorable biocompatibility and low immunogenicity.31,32 Several FDA-approved formulations, including Doxil®, Myocet®, DepoCyt®, and AmBisome®, demonstrate their successful clinical translation.33 Liposome size and structural characteristics vary depending on lipid composition, preparation methods, and post-processing conditions.34 The lipid bilayer (3–5 nm) is generally thinner than that of natural cell membranes (8–10 nm).26 Liposomal membranes, typically composed of phospholipids and cholesterol, play a critical role in drug encapsulation and stability. Synthetic phospholipids, such as 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), generally provide greater membrane stability than natural counterparts, while variations in hydrophobic tail length further modulate membrane properties.31 Moreover, incorporation of additional components into the lipid bilayer enables the development of liposome derivatives, such as transfersomes and ethosomes, thereby improving delivery efficiency.35 Despite these advantages, liposomes are susceptible to lipid oxidation, which may compromise stability and lead to drug leakage during storage.26 Furthermore, their limited chemical tunability restricts further functional modification compared with polymer-based systems. These limitations have driven the development of more robust vesicular platforms, particularly polymer-based vesicles known as polymersomes.36 Polymersomes Polymersomes are vesicular structures formed from amphiphilic block copolymers that self-assemble into polymeric bilayer membranes. They were first introduced by Discher and Eisenberg in the 1990s.37,38 These copolymers consist of hydrophilic and hydrophobic segments and can adopt various architectures, including AB, ABA, ABC, and branched configurations.39 Their self-assembled morphology is governed by the relative volume fractions of hydrophilic and hydrophobic segments, leading to structures such as spherical micelles, worm-like micelles, and vesicles. Polymersomes typically form when the hydrophilic volume fraction ranges from 0.2 to 0.4.40–43 The final morphology is determined by both thermodynamic factors, such as minimization of interfacial free energy, and kinetic factors associated with the self-assembly process.44,45 Given the diversity of block copolymers used in polymersome formation, commonly employed systems are summarized in Table 1. Hydrophilic blocks include poly(ethylene glycol) (PEG), poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA), poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC), and poly(2-methyl-2-oxazoline) (PMOXA). Hydrophobic segments commonly include poly(ε-caprolactone) (PCL), poly(lactic acid) (PLA), and poly(lactic-co-glycolide) (PLGA).5,41,46–49 The chemical tunability of these copolymers enables precise control over membrane properties, including thickness, permeability, and stability.5,39 In particular, higher-molecular-weight copolymers form thicker bilayers, thereby enhancing structural robustness and drug-loading capacity.50 Table 1Commonly Used Block Copolymers for Polymersome FormationBlock CopolymerAbbreviationCharacteristicsRef.Poly(ethylene glycol)-block-poly(butadiene)PEG-b-PBDNon-degradable42,51Poly(ethylene glycol)-block-poly(ε-caprolactone)PEG-b-PCLBiodegradable42,52Poly(ethylene glycol)-block-poly(2-(diisopropylamino)ethyl methacrylate)PEG-b-PDPApH-responsive53,54Poly(ethylene glycol)-block-poly(2-(dimethylamino)ethyl methacrylate)PEG-b-PDMAEMApH-responsive55Poly(ethylene glycol)-block-poly(N-isopropylacrylamide)PEG-b-PNIPAMThermo-responsive55,56Poly(ethylene glycol)-block-poly(propylene sulfide)PEG-b-PPSROS-responsive57,58Poly(ethylene glycol)-block-poly(lactic acid)PEG-b-PLABiodegradable42,59,60Poly(ethylene glycol)-block-poly(lactide-co-glycolide)PEG-b-PLGABiodegradable44,49Poly(ethylene glycol)-block-poly(styrene)PEG-b-PSNon-degradable56,61Poly(ethylene glycol)-block-poly(trimethylene carbonate)PEG-b-PTMCBiodegradable44,62Poly(acrylic acid)-block-poly(styrene)PAA-b-PSpH-responsive4,63Poly(N-(2-hydroxypropyl)methacrylamide)-block-poly(2-(diisopropylamino)ethyl methacrylate)PHPMA-b-PDPApH-responsive (PISA)53,64,65Poly(2-(methacryloyloxy)ethyl phosphorylcholine)-block-poly(2-(diisopropylamino)ethyl methacrylate)PMPC-b-PDPApH-responsive66Poly(ethylene oxide)-block-poly(propylene oxide)-block-poly(ethylene oxide)PEO-b-PPO-b-PEOThermo-responsive67,68Poly(2-methyl-2-oxazoline)-block-poly(dimethylsiloxane)-block-poly(2-methyl-2-oxazoline)PMOXA-b-PDMS-b-PMOXANon-degradable51,69,70 Table 1Commonly Used Block Copolymers for Polymersome FormationBlock CopolymerAbbreviationCharacteristicsRef.Poly(ethylene glycol)-block-poly(butadiene)PEG-b-PBDNon-degradable42,51Poly(ethylene glycol)-block-poly(ε-caprolactone)PEG-b-PCLBiodegradable42,52Poly(ethylene glycol)-block-poly(2-(diisopropylamino)ethyl methacrylate)PEG-b-PDPApH-responsive53,54Poly(ethylene glycol)-block-poly(2-(dimethylamino)ethyl methacrylate)PEG-b-PDMAEMApH-responsive55Poly(ethylene glycol)-block-poly(N-isopropylacrylamide)PEG-b-PNIPAMThermo-responsive55,56Poly(ethylene glycol)-block-poly(propylene sulfide)PEG-b-PPSROS-responsive57,58Poly(ethylene glycol)-block-poly(lactic acid)PEG-b-PLABiodegradable42,59,60Poly(ethylene glycol)-block-poly(lactide-co-glycolide)PEG-b-PLGABiodegradable44,49Poly(ethylene glycol)-block-poly(styrene)PEG-b-PSNon-degradable56,61Poly(ethylene glycol)-block-poly(trimethylene carbonate)PEG-b-PTMCBiodegradable44,62Poly(acrylic acid)-block-poly(styrene)PAA-b-PSpH-responsive4,63Poly(N-(2-hydroxypropyl)methacrylamide)-block-poly(2-(diisopropylamino)ethyl methacrylate)PHPMA-b-PDPApH-responsive (PISA)53,64,65Poly(2-(methacryloyloxy)ethyl phosphorylcholine)-block-poly(2-(diisopropylamino)ethyl methacrylate)PMPC-b-PDPApH-responsive66Poly(ethylene oxide)-block-poly(propylene oxide)-block-poly(ethylene oxide)PEO-b-PPO-b-PEOThermo-responsive67,68Poly(2-methyl-2-oxazoline)-block-poly(dimethylsiloxane)-block-poly(2-methyl-2-oxazoline)PMOXA-b-PDMS-b-PMOXANon-degradable51,69,70 Commonly Used Block Copolymers for Polymersome Formation Although polymersomes generally exhibit greater structural stability than liposomes, they also present limitations.36 Their relatively thick polymeric membranes result in substantially lower permeability, which can hinder efficient drug release. To address this limitation, stimuli-responsive polymers and functionalized components are often incorporated to enable controlled cargo release. Hybrid Lipopolymersomes Hybrid lipopolymersomes are vesicular nanocarriers composed of mixed lipid-polymer bilayers that integrate the advantageous properties of liposomes and polymersomes.11,71 The combination of lipid-derived biocompatibility and polymer-derived mechanical stability promotes favorable biological interactions, enhances membrane stability, and reduces premature drug leakage.72–74 Membrane stability of hybrid lipopolymersomes is strongly influenced by lipid-polymer compatibility. Because polymers typically form thicker membranes than lipids, incompatibility between the two components may induce phase separation, leading to lipid-rich and polymer-rich domains rather than a homogeneous bilayer (Figure 2).75,76 In addition, the polymer-to-lipid ratio and preparation temperature affect membrane uniformity and the physicochemical properties of hybrid lipopolymersomes.72,77 Figure 2Membrane organization in hybrid lipopolymersomes showing homogeneous mixing or phase-separated domains. Created with BioRender.com.A schematic of hybrid lipopolymersomes showing distinct membrane domains and uniform mixing. Membrane organization in hybrid lipopolymersomes showing homogeneous mixing or phase-separated domains. Created with BioRender.com. Despite these advantages, fabrication of hybrid lipopolymersomes is more complex and less scalable than that of conventional liposomes and polymersomes, owing to the requirement for precise control over lipid-polymer composition and processing conditions.73,77 Moreover, intrinsic differences between lipids and polymers can lead to structural heterogeneity, which may compromise membrane integrity, drug encapsulation efficiency, and drug delivery performance.72,78 Exosomes Exosomes are extracellular vesicles first identified in 1983 and subsequently recognized as carriers of diverse biomolecules, including RNA and signaling molecules. These endosome-derived vesicles typically range from 30–150 nm in diameter.79,80 Exosomes originate from various cell types and exhibit distinct molecular compositions. For example, platelet-derived exosomes are enriched in platelet growth factors, whereas stem cell-derived exosomes contain proliferation-related biomolecules.81,82 Their cellular origin confers high biocompatibility and low immunogenicity, supporting their potential as drug delivery carriers.9 In addition, exosomal membranes contain various proteins, lipids, and adhesion molecules that facilitate cellular recognition and uptake.81 These membrane-associated components enable exosomes to participate in natural intercellular communication pathways and may contribute to more efficient delivery of therapeutic cargos compared with fully synthetic vesicular systems.83 Unlike synthetic vesicular nanoparticles such as liposomes and polymersomes, exosomes are isolated from cell culture media rather than artificially fabricated.84 Their inherent biological complexity results in substantial compositional variability, even within the same cell source, necessitating rigorous isolation and purification techniques, including ultracentrifugation, immunoaffinity capture, and chromatography.85 In addition, exosomes exhibit limited functionalization compared with liposomes and polymersomes.86 These limitations, together with challenges related to large-scale production, batch-to-batch variability, and standardization, remain major barriers to clinical translation.87 Although exosomes exhibit limited tunability compared with synthetic systems, hybrid strategies with liposomes have been explored to improve drug loading and stability, with fusion-based hybrids showing enhanced delivery efficiency compared with native exosomes.88,89 Other Vesicular Carriers In addition to lipid- and polymer-based vesicles, alternative nanocarriers have been explored. Niosomes are composed of non-ionic surfactants, whereas proteinosomes are protein-based vesicles.23 Porphysomes, formed from porphyrin–lipid conjugates, have also been reported for drug delivery and theranostic applications.90 Although these systems demonstrate the versatility of vesicle-based nanocarriers, they remain less extensively studied than conventional vesicular carriers. To facilitate comparison among the major vesicular carriers discussed above, their key structural characteristics, advantages, and limitations are summarized in Table 2. Table 2Comparison of Representative Vesicular CarriersCarrierStructural FeatureAdvantagesLimitationsLiposomePhospholipid bilayer resembling cell membranesHigh biocompatibility, low immunogenicity, and efficient encapsulation of both hydrophilic and hydrophobic cargosSusceptible to oxidation and leakage, limited chemical tunabilityPolymersomeAmphiphilic block copolymer bilayerEnhanced mechanical stability and tunable membrane propertiesReduced membrane permeability, which may hinder drug releaseHybrid lipopolymersomeMixed lipid-polymer membraneCombines the biocompatibility of liposomes with the stability of polymersomesPhase separation and fabrication complexityExosomeNaturally derived extracellular vesicleIntrinsic biological functionality and intercellular communication capabilityHeterogeneity, purification challenges, and limited standardization Table 2Comparison of Representative Vesicular CarriersCarrierStructural FeatureAdvantagesLimitationsLiposomePhospholipid bilayer resembling cell membranesHigh biocompatibility, low immunogenicity, and efficient encapsulation of both hydrophilic and hydrophobic cargosSusceptible to oxidation and leakage, limited chemical tunabilityPolymersomeAmphiphilic block copolymer bilayerEnhanced mechanical stability and tunable membrane propertiesReduced membrane permeability, which may hinder drug releaseHybrid lipopolymersomeMixed lipid-polymer membraneCombines the biocompatibility of liposomes with the stability of polymersomesPhase separation and fabrication complexityExosomeNaturally derived extracellular vesicleIntrinsic biological functionality and intercellular communication capabilityHeterogeneity, purification challenges, and limited standardization Comparison of Representative Vesicular Carriers Drug Encapsulation within Vesicular Carriers Hydrophobic Molecules Hydrophobic molecules are encapsulated within bilayer membrane domains. This process is primarily driven by hydrophobic interactions between the drug and membrane components, supplemented by van der Waals forces, π–π stacking, and, in some cases, hydrogen bonding.91 Table 3 summarizes representative examples of hydrophobic agent encapsulation in various vesicular carriers. Liposomes, polymersomes, and hybrid lipopolymersomes have demonstrated efficient encapsulation and enhanced delivery efficiency of hydrophobic anticancer agents. Exosome-based systems have also demonstrated successful encapsulation of therapeutic agents, with enhanced intracellular delivery efficiency and the ability to overcome endosomal entrapment in drug-resistant cancer models.92 The loading capacity and efficiency of hydrophobic molecules are strongly influenced by the membrane properties of vesicular carriers.67,74,93 Liposomes, which possess relatively thin lipid bilayers, often exhibit limited loading capacity, whereas polymersomes, with thicker membranes, can accommodate larger amounts of hydrophobic cargo. In contrast, exosomes, as naturally derived vesicles, present challenges in drug loading owing to limited controllability and lower loading efficiency. Table 3Therapeutic Applications of Vesicle-Based NanocarriersDrug Delivery SystemHydrophilic AgentsHydrophobic AgentsApplicationRef.LiposomePC (unspecified), cholesterol, EPA (folic acid-functionalized)QuercetinTargeted chemotherapy for cancer1LiposomeDSPE-PEG2K-AE147, HSPC, cholesterolDocetaxelTargeted chemotherapy for breast cancer94PolymersomePEG-b-PCLPaclitaxelChemotherapy for glioma95Hybrid lipopolymersomeDPPC, CTTP-cholesterol, PEG-b-P(MAAc-g-His)-NH2CeramidepH-responsive mitochondrial-targeting therapy in breast cancer96Hybrid lipopolymersomeDPPC, F127Hypericin (photosensitizer)Photodynamic therapy (photosensitizer delivery)97Hybrid exosome–liposomeDSPE-PEG2K, DPPC, cholesterol, human blood-derived exosomePalbociclibTargeted chemotherapy for breast cancer88CerasomeDSPE-PEG2K-iRGD, DSPC, DOPC, silane-containing lipid (cerasome-forming lipid), porphyrin-conjugated lipidSR-717 (STING agonist)Targeted immunotherapy for TNBC15LiposomeDSPE-PEG2K-DVar7, DSPE-PEG2K, DOPE, CHEMSDox-HClEnhanced chemotherapy for cancer98LiposomeDSPE-PEG2K, HSPC, cholesterol, DSPE-PEG3.4K-RGDDox-HClTargeted chemotherapy for colorectal cancer99LiposomeDSPE-PEG2K, DSPC, DOPE, MSPC, cholesterolDox-HClUltrasound-triggered chemotherapy for TNBC27LiposomeHSPC, HA-DOCADox-HCl, HyaluronidaseTime-programmed drug delivery for cancer chemotherapy100LiposomeDSPE-PEG2K, DPPC, DSPCGemcitabine-HClChemotherapy for pancreatic ductal adenocarcinoma101LiposomeDSPC, DOTAP, cholesterolGentamicin sulfateElectroporation-enhanced drug delivery102LiposomeDSPE-thioketal-PEG-RVG29, DOPE, cholesterolPuerarinTargeted therapy for ischemic stroke103LiposomeDSPE-PEG2K, DPPC, cholesterol5-FU, metformin, Bismuth nanosheetsaPhotothermal- and thermo-responsive chemotherapy for colon cancer104PolymersomePHPMA-b-PDPADox-HClpH-responsive chemotherapy for cancer65PolymersomePVCL-b-PLLDox-HClDual pH- and thermo-responsive chemotherapy for breast cancer105PolymersomePHPMA-b-PPPhADox-HClChemotherapy for lymphoma64PolymersomePHPMA-b-PbAPEDox-HClROS-responsive chemotherapy for cancer64PolymersomePEO-b-P(DEA-stat-MEMA)Dox-HClUltrasound-triggered chemotherapy for breast cancer106PolymersomePEG-PLGA, maleimid-PEG-PLGA (lactoferrin-conjugated)S14G-humanian peptideBrain-targeted peptide delivery49PolymersomePHEA-b-PDEGEA, PTMAEA-b-PDEGEA, mannosylated PHEA-b-PDEGEAOvalbumin, siRNA(VEGF-A, Bcl2)Protein/siRNA delivery for vaccination and cancer therapy37PolymersomePEG-b-PPS (erythrocyte membrane coating)SsoPox-IIIC1 (PLL)bIn vivo detoxification of organophosphorus compounds57PolymersomeAmphiphilic random copolymercAmphiphilic RB-K2dPhotodynamic therapy for melanoma7Hybrid lipopolymersomeDPPC, PEG-b-PLARhodamine6GEnhanced tumor accumulation for cancer therapy74Hybrid lipopolymersomeDSPC, cholesterol, P(DEAMEA-co-BMA)-b-P(MannEMA)StreptomycinpH-responsive intracellular antibiotic delivery107ExosomeMenSCs-derived exosomemiR-let-7Alleviation of pulmonary fibrosis and alveolar epithelial cell injury108Exosome293-F-derived exosome (iRGD-engineered)siMYCTumor-targeted therapy for TNBC9ExosomeMDA-MB-231e-derived exosome, DSPE-peptide conjugates (anti-CD47, anti-M2)CrocinTumor microenvironment- and macrophage-targeted therapy109ExosomeBovine milk-derived exosomeCisplatinCytosolic chemotherapy for cisplatin-resistant ovarian cancer92ExosomeMDA-MB-231-derived exosomeCisplatin, anti-CD47Targeted chemo-immunotherapy for NSCLC110Hybrid exosome–liposomeBovine milk-derived exosome, cholesterol, DMPCSemaglutideEnhanced oral peptide delivery10Hybrid exosome–liposomeBovine milk-derived exosome, cholesterol, DPPCSemaglutideEnhanced oral peptide delivery10Hybrid exosome–liposomeBovine milk-derived exosome, cholesterol, DSPCSemaglutideEnhanced oral peptide delivery10Hybrid exosome–liposomeL-α-PC, DOPE-phenylboronate, M2 macrophage-derived exosomeGinsenoside Rb2Mitochondria-targeted therapy for spinal cord injury111Hybrid exosome–liposomePC (so-derived), stearylamine, BM-MSCs-derived exosomeCaffeineTargeted antifibrotic therapy for liver fibrosis89LiposomeLecithin, cholesterol, DSPE-PEG (SP94/TAT co-modified)Dox-HClDocetaxelDual-targeted combination therapy for liver cancer112LiposomePC (egg), cholesterol, CPBA-chitosan conjugateDox-HClR848Targeted chemo-immunotherapy for bladder cancer16LiposomeDSPE-PEG2K, DOPC, cholesterolDox-HClCurcuminMDR-reversing combination chemotherapy113LiposomeDSPE-PEG2K, POPS, ginsenoside Rg3siRNA (anti-survivin, complexed with chitooligosaccharide)PaclitaxelSynergistic chemo-gene therapy3LiposomeDSPE-PEG2K, DOPC, cholesterolCisplatinFisetinSynergistic combination therapy for lung cancer114PolymersomePEG-b-PLADox-HClVerteporfinChemo-sonodynamic combination therapy for pancreatic cancer60PolymersomeHyaluronan-cholesterol, hyaluronan-sphingosineHRH peptide (anti-VEGF peptide)SphingosineCombination therapy for ocular neovascularization115PolymersomePEG-b-PDTCTEMAf, PDTCTEMAIndocyanine GreenCuproptosis-photothermal combination therapy116PolymersomePEG-b-PCLCordycepinPhenylboronic acidCombination therapy for osteoarthritis treatment117Hybrid lipopolymersomeDSEP-PEG2K, DPPC, DOPE, DOTAP, PEG-b-PLACisplatin caprylateABCC3 siRNACombination therapy for lung cancer118ExosomeSU-DHL-4-derived exosomesiBTKIsoimperatorinSynergistic chemogene therapy for DLBCL119Hybrid exosome–liposomeDSPE-PEG2K, DPPC, MSPC, CD47/GM-CSF-engineered fibroblast-derived exosomeGM-CSFDocetaxelChemoimmunotherapy for metastatic peritoneal cancer120Hybrid exosome–liposomeDSPE-PEG2K, DOPC, cholesterol, 4T1-derived exosomeKetoconazole, BMS-202 (PD-L1 antibodies)Indocyanine greenEnhanced immunotherapy and photothermal therapy for metastatic breast cancer121Notes: aBimuth nanosheets: inorganic nanomaterial used for photothermal therapy (not classified as a hydrophilic or hydrophobic drug). bSsoPox-IIIC1(PLL): multiple mutant phosphotriesterase-like lactonase derived from Saccharolobus solfataricus. cAmphiphilic random copolymer: composed of hydrophilic poly(ethylene glycol) methacrylate and hydrophobic decyl methacrylate. dRB-K2: hydrophobic, membrane-associated cargo due to its incorporation into the polymersome membrane. eMDA-MB-231-derived exosomes: referred to as “MDA-2B1” or “MDA cells” in the original study. fPEG-PDTCTEMA: block copolymer composed of poly(ethylene glycol) and PDTCTEMA.Abbreviations: BM-MSCs, bone marrow mesenchymal stem cells; CHEMS, cholesteryl hemisuccinate; CPBA-chitosan conjugate, 4-carboxyphenylboronic acid-modified chitosan; CTTP-cholesterol, 3-carboxypropyl triphenylphosphonium bromide-cholesterol; DLBCL, diffuse large B-cell lymphoma; DMPC, 1,2-dimyristoyl-sn-glycero-3-phosphocholine; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOTAP, 1,2-dioleoyloxy-3-trimethylammonium-propane chloride; Dox, doxorubicin; DPPC, CTTP-cholesterol, 3-carboxypropyl triphenylphosphonium bromide-cholesterol; DSPE-PEG, 1,2-distearoyl-sn-glycero-3-phosphoethanolamin-N-poly(ethylene glycol); DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; DTCTEMA, diethylcarbamo(dithioperoxo)thioate ethyl methacrylate (name adopted from the original paper); EPA, eicosapentaenoic acid; GM-CSF, granulocyte-macrophage colony-stimulating factor; HA-DOCA, hyaluronic acid–deoxycholic acid; HSPC, hydrogenated soy phosphatidylcholine; MenSCs, menstrual blood-derived stem cells; MSPC, 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine; NSCLC, non-small cell lung cancer; PC, phosphatidylcholine; PEG-b-P(MAAc-g-His)-NH2, poly(ethylene glycol)-block-poly(methacrylic acid-g-histidine)-amine; P(DEAMEA-co-BMA)-b-P(MannEMA), poly(2-(diethylamino)ethyl methacrylate-co-butyl methacrylate)-block-poly(2-(mannosyloxy)ethyl methacrylate); PEO-b-P(DEA-stat-MEMA), poly(ethylene oxide)-block-poly(2-(dimethylamino)ethyl methacrylate)-stat-poly(methoxyethyl methacrylate); PHEA-b-PDEGEA, poly(hydroxyethyl acrylate)-block-poly(diethylene glycol ethyl ether acrylate); PHPMA-b-PPPhA, poly(N-(2-hydroxypropyl)methacrylamide)-block-poly(N-(4-isopropylphenylacetamide)ethyl methacrylate); PHPMA-PbAPE, poly(N-(2-hydroxypropyl)methacrylamide)-block-poly(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl methacrylate); POPS, 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine; PTMAEA-b-PDEGEA, poly(trimethylamino ethyl acrylate)-block-poly(diethylene glycol ethyl ether acrylate); PVCL-b-PLL, poly(N-vinylcaprolactam)-block-poly(L-lysine); TNBC, triple-negative breast cancer. Table 3Therapeutic Applications of Vesicle-Based NanocarriersDrug Delivery SystemHydrophilic AgentsHydrophobic AgentsApplicationRef.LiposomePC (unspecified), cholesterol, EPA (folic acid-functionalized)QuercetinTargeted chemotherapy for cancer1LiposomeDSPE-PEG2K-AE147, HSPC, cholesterolDocetaxelTargeted chemotherapy for breast cancer94PolymersomePEG-b-PCLPaclitaxelChemotherapy for glioma95Hybrid lipopolymersomeDPPC, CTTP-cholesterol, PEG-b-P(MAAc-g-His)-NH2CeramidepH-responsive mitochondrial-targeting therapy in breast cancer96Hybrid lipopolymersomeDPPC, F127Hypericin (photosensitizer)Photodynamic therapy (photosensitizer delivery)97Hybrid exosome–liposomeDSPE-PEG2K, DPPC, cholesterol, human blood-derived exosomePalbociclibTargeted chemotherapy for breast cancer88CerasomeDSPE-PEG2K-iRGD, DSPC, DOPC, silane-containing lipid (cerasome-forming lipid), porphyrin-conjugated lipidSR-717 (STING agonist)Targeted immunotherapy for TNBC15LiposomeDSPE-PEG2K-DVar7, DSPE-PEG2K, DOPE, CHEMSDox-HClEnhanced chemotherapy for cancer98LiposomeDSPE-PEG2K, HSPC, cholesterol, DSPE-PEG3.4K-RGDDox-HClTargeted chemotherapy for colorectal cancer99LiposomeDSPE-PEG2K, DSPC, DOPE, MSPC, cholesterolDox-HClUltrasound-triggered chemotherapy for TNBC27LiposomeHSPC, HA-DOCADox-HCl, HyaluronidaseTime-programmed drug delivery for cancer chemotherapy100LiposomeDSPE-PEG2K, DPPC, DSPCGemcitabine-HClChemotherapy for pancreatic ductal adenocarcinoma101LiposomeDSPC, DOTAP, cholesterolGentamicin sulfateElectroporation-enhanced drug delivery102LiposomeDSPE-thioketal-PEG-RVG29, DOPE, cholesterolPuerarinTargeted therapy for ischemic stroke103LiposomeDSPE-PEG2K, DPPC, cholesterol5-FU, metformin, Bismuth nanosheetsaPhotothermal- and thermo-responsive chemotherapy for colon cancer104PolymersomePHPMA-b-PDPADox-HClpH-responsive chemotherapy for cancer65PolymersomePVCL-b-PLLDox-HClDual pH- and thermo-responsive chemotherapy for breast cancer105PolymersomePHPMA-b-PPPhADox-HClChemotherapy for lymphoma64PolymersomePHPMA-b-PbAPEDox-HClROS-responsive chemotherapy for cancer64PolymersomePEO-b-P(DEA-stat-MEMA)Dox-HClUltrasound-triggered chemotherapy for breast cancer106PolymersomePEG-PLGA, maleimid-PEG-PLGA (lactoferrin-conjugated)S14G-humanian peptideBrain-targeted peptide delivery49PolymersomePHEA-b-PDEGEA, PTMAEA-b-PDEGEA, mannosylated PHEA-b-PDEGEAOvalbumin, siRNA(VEGF-A, Bcl2)Protein/siRNA delivery for vaccination and cancer therapy37PolymersomePEG-b-PPS (erythrocyte membrane coating)SsoPox-IIIC1 (PLL)bIn vivo detoxification of organophosphorus compounds57PolymersomeAmphiphilic random copolymercAmphiphilic RB-K2dPhotodynamic therapy for melanoma7Hybrid lipopolymersomeDPPC, PEG-b-PLARhodamine6GEnhanced tumor accumulation for cancer therapy74Hybrid lipopolymersomeDSPC, cholesterol, P(DEAMEA-co-BMA)-b-P(MannEMA)StreptomycinpH-responsive intracellular antibiotic delivery107ExosomeMenSCs-derived exosomemiR-let-7Alleviation of pulmonary fibrosis and alveolar epithelial cell injury108Exosome293-F-derived exosome (iRGD-engineered)siMYCTumor-targeted therapy for TNBC9ExosomeMDA-MB-231e-derived exosome, DSPE-peptide conjugates (anti-CD47, anti-M2)CrocinTumor microenvironment- and macrophage-targeted therapy109ExosomeBovine milk-derived exosomeCisplatinCytosolic chemotherapy for cisplatin-resistant ovarian cancer92ExosomeMDA-MB-231-derived exosomeCisplatin, anti-CD47Targeted chemo-immunotherapy for NSCLC110Hybrid exosome–liposomeBovine milk-derived exosome, cholesterol, DMPCSemaglutideEnhanced oral peptide delivery10Hybrid exosome–liposomeBovine milk-derived exosome, cholesterol, DPPCSemaglutideEnhanced oral peptide delivery10Hybrid exosome–liposomeBovine milk-derived exosome, cholesterol, DSPCSemaglutideEnhanced oral peptide delivery10Hybrid exosome–liposomeL-α-PC, DOPE-phenylboronate, M2 macrophage-derived exosomeGinsenoside Rb2Mitochondria-targeted therapy for spinal cord injury111Hybrid exosome–liposomePC (so-derived), stearylamine, BM-MSCs-derived exosomeCaffeineTargeted antifibrotic therapy for liver fibrosis89LiposomeLecithin, cholesterol, DSPE-PEG (SP94/TAT co-modified)Dox-HClDocetaxelDual-targeted combination therapy for liver cancer112LiposomePC (egg), cholesterol, CPBA-chitosan conjugateDox-HClR848Targeted chemo-immunotherapy for bladder cancer16LiposomeDSPE-PEG2K, DOPC, cholesterolDox-HClCurcuminMDR-reversing combination chemotherapy113LiposomeDSPE-PEG2K, POPS, ginsenoside Rg3siRNA (anti-survivin, complexed with chitooligosaccharide)PaclitaxelSynergistic chemo-gene therapy3LiposomeDSPE-PEG2K, DOPC, cholesterolCisplatinFisetinSynergistic combination therapy for lung cancer114PolymersomePEG-b-PLADox-HClVerteporfinChemo-sonodynamic combination therapy for pancreatic cancer60PolymersomeHyaluronan-cholesterol, hyaluronan-sphingosineHRH peptide (anti-VEGF peptide)SphingosineCombination therapy for ocular neovascularization115PolymersomePEG-b-PDTCTEMAf, PDTCTEMAIndocyanine GreenCuproptosis-photothermal combination therapy116PolymersomePEG-b-PCLCordycepinPhenylboronic acidCombination therapy for osteoarthritis treatment117Hybrid lipopolymersomeDSEP-PEG2K, DPPC, DOPE, DOTAP, PEG-b-PLACisplatin caprylateABCC3 siRNACombination therapy for lung cancer118ExosomeSU-DHL-4-derived exosomesiBTKIsoimperatorinSynergistic chemogene therapy for DLBCL119Hybrid exosome–liposomeDSPE-PEG2K, DPPC, MSPC, CD47/GM-CSF-engineered fibroblast-derived exosomeGM-CSFDocetaxelChemoimmunotherapy for metastatic peritoneal cancer120Hybrid exosome–liposomeDSPE-PEG2K, DOPC, cholesterol, 4T1-derived exosomeKetoconazole, BMS-202 (PD-L1 antibodies)Indocyanine greenEnhanced immunotherapy and photothermal therapy for metastatic breast cancer121Notes: aBimuth nanosheets: inorganic nanomaterial used for photothermal therapy (not classified as a hydrophilic or hydrophobic drug). bSsoPox-IIIC1(PLL): multiple mutant phosphotriesterase-like lactonase derived from Saccharolobus solfataricus. cAmphiphilic random copolymer: composed of hydrophilic poly(ethylene glycol) methacrylate and hydrophobic decyl methacrylate. dRB-K2: hydrophobic, membrane-associated cargo due to its incorporation into the polymersome membrane. eMDA-MB-231-derived exosomes: referred to as “MDA-2B1” or “MDA cells” in the original study. fPEG-PDTCTEMA: block copolymer composed of poly(ethylene glycol) and PDTCTEMA.Abbreviations: BM-MSCs, bone marrow mesenchymal stem cells; CHEMS, cholesteryl hemisuccinate; CPBA-chitosan conjugate, 4-carboxyphenylboronic acid-modified chitosan; CTTP-cholesterol, 3-carboxypropyl triphenylphosphonium bromide-cholesterol; DLBCL, diffuse large B-cell lymphoma; DMPC, 1,2-dimyristoyl-sn-glycero-3-phosphocholine; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOTAP, 1,2-dioleoyloxy-3-trimethylammonium-propane chloride; Dox, doxorubicin; DPPC, CTTP-cholesterol, 3-carboxypropyl triphenylphosphonium bromide-cholesterol; DSPE-PEG, 1,2-distearoyl-sn-glycero-3-phosphoethanolamin-N-poly(ethylene glycol); DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; DTCTEMA, diethylcarbamo(dithioperoxo)thioate ethyl methacrylate (name adopted from the original paper); EPA, eicosapentaenoic acid; GM-CSF, granulocyte-macrophage colony-stimulating factor; HA-DOCA, hyaluronic acid–deoxycholic acid; HSPC, hydrogenated soy phosphatidylcholine; MenSCs, menstrual blood-derived stem cells; MSPC, 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine; NSCLC, non-small cell lung cancer; PC, phosphatidylcholine; PEG-b-P(MAAc-g-His)-NH2, poly(ethylene glycol)-block-poly(methacrylic acid-g-histidine)-amine; P(DEAMEA-co-BMA)-b-P(MannEMA), poly(2-(diethylamino)ethyl methacrylate-co-butyl methacrylate)-block-poly(2-(mannosyloxy)ethyl methacrylate); PEO-b-P(DEA-stat-MEMA), poly(ethylene oxide)-block-poly(2-(dimethylamino)ethyl methacrylate)-stat-poly(methoxyethyl methacrylate); PHEA-b-PDEGEA, poly(hydroxyethyl acrylate)-block-poly(diethylene glycol ethyl ether acrylate); PHPMA-b-PPPhA, poly(N-(2-hydroxypropyl)methacrylamide)-block-poly(N-(4-isopropylphenylacetamide)ethyl methacrylate); PHPMA-PbAPE, poly(N-(2-hydroxypropyl)methacrylamide)-block-poly(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl methacrylate); POPS, 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine; PTMAEA-b-PDEGEA, poly(trimethylamino ethyl acrylate)-block-poly(diethylene glycol ethyl ether acrylate); PVCL-b-PLL, poly(N-vinylcaprolactam)-block-poly(L-lysine); TNBC, triple-negative breast cancer. Therapeutic Applications of Vesicle-Based Nanocarriers Notes: aBimuth nanosheets: inorganic nanomaterial used for photothermal therapy (not classified as a hydrophilic or hydrophobic drug). bSsoPox-IIIC1(PLL): multiple mutant phosphotriesterase-like lactonase derived from Saccharolobus solfataricus. cAmphiphilic random copolymer: composed of hydrophilic poly(ethylene glycol) methacrylate and hydrophobic decyl methacrylate. dRB-K2: hydrophobic, membrane-associated cargo due to its incorporation into the polymersome membrane. eMDA-MB-231-derived exosomes: referred to as “MDA-2B1” or “MDA cells” in the original study. fPEG-PDTCTEMA: block copolymer composed of poly(ethylene glycol) and PDTCTEMA. Abbreviations: BM-MSCs, bone marrow mesenchymal stem cells; CHEMS, cholesteryl hemisuccinate; CPBA-chitosan conjugate, 4-carboxyphenylboronic acid-modified chitosan; CTTP-cholesterol, 3-carboxypropyl triphenylphosphonium bromide-cholesterol; DLBCL, diffuse large B-cell lymphoma; DMPC, 1,2-dimyristoyl-sn-glycero-3-phosphocholine; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOTAP, 1,2-dioleoyloxy-3-trimethylammonium-propane chloride; Dox, doxorubicin; DPPC, CTTP-cholesterol, 3-carboxypropyl triphenylphosphonium bromide-cholesterol; DSPE-PEG, 1,2-distearoyl-sn-glycero-3-phosphoethanolamin-N-poly(ethylene glycol); DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; DTCTEMA, diethylcarbamo(dithioperoxo)thioate ethyl methacrylate (name adopted from the original paper); EPA, eicosapentaenoic acid; GM-CSF, granulocyte-macrophage colony-stimulating factor; HA-DOCA, hyaluronic acid–deoxycholic acid; HSPC, hydrogenated soy phosphatidylcholine; MenSCs, menstrual blood-derived stem cells; MSPC, 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine; NSCLC, non-small cell lung cancer; PC, phosphatidylcholine; PEG-b-P(MAAc-g-His)-NH2, poly(ethylene glycol)-block-poly(methacrylic acid-g-histidine)-amine; P(DEAMEA-co-BMA)-b-P(MannEMA), poly(2-(diethylamino)ethyl methacrylate-co-butyl methacrylate)-block-poly(2-(mannosyloxy)ethyl methacrylate); PEO-b-P(DEA-stat-MEMA), poly(ethylene oxide)-block-poly(2-(dimethylamino)ethyl methacrylate)-stat-poly(methoxyethyl methacrylate); PHEA-b-PDEGEA, poly(hydroxyethyl acrylate)-block-poly(diethylene glycol ethyl ether acrylate); PHPMA-b-PPPhA, poly(N-(2-hydroxypropyl)methacrylamide)-block-poly(N-(4-isopropylphenylacetamide)ethyl methacrylate); PHPMA-PbAPE, poly(N-(2-hydroxypropyl)methacrylamide)-block-poly(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl methacrylate); POPS, 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine; PTMAEA-b-PDEGEA, poly(trimethylamino ethyl acrylate)-block-poly(diethylene glycol ethyl ether acrylate); PVCL-b-PLL, poly(N-vinylcaprolactam)-block-poly(L-lysine); TNBC, triple-negative breast cancer. Hydrophilic Molecules Hydrophilic molecules are encapsulated within the internal aqueous core, which is surrounded by the bilayer membrane (Figure 3). In vesicular carriers, polar lipid head groups or hydrophilic polymer segments form this aqueous core, enabling the encapsulation of hydrophilic molecules and improving delivery efficiency while reducing rapid in vivo clearance. Figure 3Morphology of vesicular carriers following encapsulation of hydrophilic molecules within the aqueous core. (a) Blank vesicles without encapsulated cargo. Adapted from (Perera et al, 2022)71, with permission from ACS Publications (License No. 6255240561798). (b) Doxorubicin hydrochloride-loaded vesicles. Adapted from (Kim et al, 2022)71 MDPI, distributed under the Creative Commons Attribution (CC BY 4.0) license.Electron micrographs comparing blank vesicles (a) and doxorubicin hydrochloride-loaded vesicles (b). Morphology of vesicular carriers following encapsulation of hydrophilic molecules within the aqueous core. (a) Blank vesicles without encapsulated cargo. Adapted from (Perera et al, 2022)71, with permission from ACS Publications (License No. 6255240561798). (b) Doxorubicin hydrochloride-loaded vesicles. Adapted from (Kim et al, 2022)71 MDPI, distributed under the Creative Commons Attribution (CC BY 4.0) license. Efficient encapsulation of hydrophilic molecules requires a sufficiently large aqueous core, which directly determines loading capacity.93 Various vesicular carriers have successfully encapsulated and delivered hydrophilic small molecules and biomacromolecules, including peptides and nucleic acids (Table 3). Encapsulation in liposomes improves the stability and bioavailability of therapeutic agents, whereas polymersomes provide enhanced protection against enzymatic degradation and enable sustained release owing to their more rigid membrane properties.2,7,115 Exosomes have been applied for nucleic acid delivery, demonstrating improved cellular uptake and intracellular delivery efficiency.9,10,108 Overall, vesicular carriers protect encapsulated molecules and enable controlled drug release in biological environments. Co-Encapsulated Molecules The structural architecture of vesicular carriers enables the simultaneous encapsulation of hydrophobic and hydrophilic molecules within a single system, thereby enhancing formulation versatility and enabling synergistic therapeutic effects (Table 3). Liposomes and polymersomes have been extensively investigated for the co-delivery of chemical and biological agents to modulate multiple therapeutic pathways concurrently.3,16,113,117 These strategies have demonstrated the potential to overcome multidrug resistance, for example, through co-delivery with P-glycoprotein inhibitors or small interfering RNA (siRNA), resulting in enhanced apoptotic responses.3,113 In the case of exosomes, although encapsulation efficiency is relatively low, their inherent low immunogenicity and reduced drug leakage make them promising platforms for co-delivery.110,119 From Passive to Stimuli-Responsive Carriers Most developed vesicular carriers are nanoscale, typically smaller than 200 nm, which allows partial evasion of nonspecific clearance by the reticuloendothelial system.16,30 In tumor-targeted delivery, the leaky tumor vasculature (100–780 nm), compared with that in normal tissues (4–10 nm), facilitates preferential accumulation via the enhanced permeability and retention (EPR) effect.18 However, passive accumulation alone is insufficient to achieve optimal therapeutic efficacy. Effective drug delivery requires deep tumor penetration, efficient cellular internalization, and avoidance of intracellular degradation and efflux. In particular, successful cytosolic delivery of therapeutic cargos necessitates efficient endosomal escape.16,122 To overcome these limitations, pathological tissues, such as tumors and inflamed tissues, exhibit distinct microenvironmental features compared with normal tissues, including acidic pH, elevated levels of reactive oxygen species (ROS), and aberrant enzyme expression. These features provide opportunities for targeted drug delivery.123 Stimuli-responsive vesicular carriers exploit these internal cues or externally applied triggers to achieve site-specific drug release and enhanced intracellular delivery (Figure 4). This approach represents a paradigm shift from passive accumulation to controlled, stimuli-responsive delivery, thereby improving therapeutic efficacy and minimizing off-target toxicity.13 Figure 4Schematic illustration of internal and external stimuli-triggered drug release in vesicular nanocarriers. Created with BioRender.com.The illustration shows two main sections. On the left, it depicts vesicles, including liposome, polymersome and exosome. A vesicle is shown with hydrophilic agents inside and hydrophobic agents in the membrane. On the right, it illustrates stimuli-responsive vesicles. A vesicle is shown with a targeting moiety. External stimuli listed are light, magnetic field, electric field, ultrasound and heat. Internal stimuli include pH, enzyme and redox. The vesicle is depicted interacting with a cellular environment, indicating targeted delivery and response to stimuli.Diagram of vesicles and stimuli-responsive vesicles with internal and external stimuli. Schematic illustration of internal and external stimuli-triggered drug release in vesicular nanocarriers. Created with BioRender.com. Internal Stimuli-Responsive Systems pH The mildly acidic tumor microenvironment, driven by enhanced glycolysis and poor perfusion, has been widely exploited for pH-responsive drug delivery. In such systems, carriers accumulate via the enhanced EPR effect and subsequently release their payload under acidic conditions.124,125 Additionally, pH-triggered protonation can facilitate endosomal escape through the proton sponge effect.14,126,127 For example, acid-responsive liposomes composed of the pH-sensitive lipid DOPE and the peptide DVar7 exhibit enhanced membrane insertion via acid-induced conformational changes of the peptide, resulting in rapid drug release within lysosomal compartments.98 In another study, poly(2-(diisopropylamino)ethyl methacrylate) (PDPA)-based polymersomes undergo protonation of diisopropylamino groups under acidic conditions64 (Figure 5a), rendering PDPA hydrophilic and triggering cargo release (Figure 5b). The pH-sensitive properties further enhance in vivo therapeutic efficacy (Figure 5c). Similarly, liposome–exosome hybrid vesicles derived from milk exhibit acid-triggered hydrazone bond cleavage, inducing structural transformation and improving mucus penetration and gastric epithelial transport, thereby enhancing oral peptide delivery.128 Figure 5pH-responsive PDPA-based polymersome. (a) Chemical structure of the pH-responsive polymer and schematic illustration of the vesicle membrane. (b) Cumulative drug release profiles under different pH conditions. (c) Schematic illustration of the pH-responsive behavior and corresponding survival probability. Adapted from (Jager et al, 2024)64, ACS Publications, distributed under the Creative Commons Attribution (CC BY 4.0) license.Image A depicts a pH-responsive polymer structure and polymersome membrane cross-section. Image B shows a graph of DOX release over time, with conditions: PHPMA-b-PDPA at pH 7.4, with/without H2O2 1 mM and at pH 5.3, with/without H2O2 1 mM. Release is faster at pH 5.3 and with H2O2. Image C illustrates stimuli-responsive polymersomes among red blood cells, with a magnifying glass highlighting details. A survival plot shows survival probability over treatment days, comparing non-responsive, pH-responsive and ROS-responsive conditions, with step-like curves. A schematic illustration of a pH-responsive polymersome undergoing structural disruption under acidic conditions.A three-part scientific figure illustrating pH-responsive PDPA-based polymersomes, drug release profiles, and survival curves. pH-responsive PDPA-based polymersome. (a) Chemical structure of the pH-responsive polymer and schematic illustration of the vesicle membrane. (b) Cumulative drug release profiles under different pH conditions. (c) Schematic illustration of the pH-responsive behavior and corresponding survival probability. Adapted from (Jager et al, 2024)64, ACS Publications, distributed under the Creative Commons Attribution (CC BY 4.0) license. However, their therapeutic efficacy may be limited by the small pH differences between tumor and normal tissues, highlighting the need for additional targeting or multi-stimuli approaches.129 Enzyme Enzyme-responsive systems exploit aberrant enzyme expression in pathological environments.130 In tumors, overexpressed enzymes such as matrix metalloproteinases (MMPs), secretory phospholipase A2 (sPLA2), and NAD(P)H quinone oxidoreductase-1 (NQO1) can cleave specific linkers and destabilize vesicular membranes.123 MMPs cleave peptide linkers, whereas sPLA2 hydrolyzes phospholipids, thereby disrupting membranes. Intracellular NQO1 can trigger disassembly of quinone-containing vesicular systems.130,131 In addition, hyaluronidase is overexpressed in certain tumors with hyaluronic acid-rich extracellular matrices, enabling hyaluronic acid-based vesicular carriers for tumor-targeted delivery.100 Exosomes functionalized with an MMP-2-cleavable peptide motif (PVGLIG) have been used for tumor-specific peptide delivery.109 Upon enzymatic cleavage, the released peptides self-assemble into fibrous nanostructures, thereby enhancing tumor retention and macrophage-mediated uptake. Similarly, polymersomes incorporating quinone trimethyl lock–capped self-immolative linkers and quinone-bridged photosensitizers respond to NQO1-mediated quinone reduction following cellular internalization.132 This reduction triggers self-immolative disassembly and restores photodynamic activities. In another study, liposomes composed of hyaluronic acid–deoxycholic acid conjugates and hydrogenated soy phosphatidylcholine, co-encapsulating doxorubicin and hyaluronidase, demonstrated hyaluronidase-mediated degradation and structural disassembly for programmed drug release.100 However, variability in enzyme expression across patients and tumor types may affect therapeutic consistency, necessitating combination with complementary targeting strategies.132 Redox Redox gradients between normal and tumor tissues, particularly elevated intracellular glutathione (GSH) and ROS levels, have been widely exploited for redox-responsive systems. Intracellular GSH concentrations (1–2 mM) are substantially higher than extracellular concentrations (2–20 μM) and are further elevated in cancer cells (2–10 mM).17,133 These differences have been utilized in vesicular systems that incorporate reducible linkages, such as disulfide bonds, which are cleaved in the reductive intracellular tumor environment.17 In parallel, ROS-responsive systems exploit elevated oxidative stress in pathological tissues. Common ROS-cleavable linkers include thioketal and thioacetal groups, which degrade in the presence of ROS. Phenylboronic acid derivatives are also widely used, undergoing oxidation to phenols and boric acid, leading to membrane degradation.134,135 Several studies have demonstrated the effectiveness of redox-responsive vesicles for intracellular drug delivery. For instance, diethyldithiocarbamate (DTC) was conjugated to a polymer backbone via disulfide linkages to form a redox-responsive prodrug, which was used to construct polymersomes encapsulating indocyanine green (ICG).116 These vesicles undergo GSH-triggered disassembly in tumor cells, resulting in the simultaneous release of ICG and DTC. In another study, puerarin-loaded thioketal-based ROS-responsive liposomes were developed for ischemic stroke therapy.103 Elevated ROS levels in ischemic cerebral tissue cleaved thioketal linkages, triggering drug release. In addition, hybrid vesicles composed of ROS-responsive phenylboronate-linked liposomes fused with M2 macrophage-derived exosomes have been developed for spinal cord injury treatment.111 Elevated ROS levels at the injury site destabilize the vesicular membrane, enabling site-specific release of ginsenoside Rb2. Despite these advances, redox-responsive systems may exhibit off-target activation in tissues with physiologically high GSH levels, such as the liver.136 This limitation highlights the need for improved spatiotemporal control, potentially through integration with externally triggered systems. External Stimuli-Responsive Systems In addition to internal stimuli-responsive strategies, externally applied stimuli provide an additional level of control over drug release. External stimuli, including magnetic fields, electric fields, ultrasound, and heat, enable spatiotemporal regulation of drug release at target sites,137 thereby improving site-specific delivery while minimizing systemic toxicity. Light Light is a noninvasive stimulus that enables precise spatial and temporal drug release. Based on wavelength, light is classified into ultraviolet (UV), visible (Vis), and near-infrared (NIR) regions.138 Visible light penetrates tissues only up to approximately 1 mm, whereas NIR light achieves deeper tissue penetration, enabling activation at greater depths.138,139 Light irradiation can induce chemical transformations or generate ROS, thereby triggering drug release.140 Light-responsive vesicular carriers are typically engineered by incorporating photoactive moieties such as azobenzene, spiropyran, and o-nitrobenzyl groups, which operate via photoisomerization or photocleavage mechanisms.137 Azobenzene undergoes reversible trans-to-cis isomerization upon light irradiation, increasing molecular polarity and membrane permeability, thereby facilitating drug release.140 Similarly, spiropyran undergoes photoisomerization to a more hydrophilic merocyanine form upon UV irradiation, thereby increasing membrane permeability.139 In contrast, o-nitrobenzyl groups undergo irreversible photocleavage, enabling PEG detachment or polymer backbone degradation, which promotes drug release.140 For example, a tetrodotoxin-loaded meltable polycarbonate polymersome undergoes a Nile blue-mediated photothermal phase transition upon light irradiation, enabling controlled drug release with minimal premature leakage.141 Similarly, NIR-responsive polymersomes incorporating photocleavable 2-nitrobenzyl groups and upconversion nanoparticles (UCNPs) convert NIR light into UV emission, inducing bond cleavage and increasing membrane permeability142 (Figure 6a). Structural changes were confirmed by proton nuclear magnetic resonance (1H NMR) spectroscopy (Figure 6b), accompanied by time-dependent increases in membrane permeability (Figure 6c), ultimately resulting in cargo release. To improve tissue penetration, UCNPs have been widely incorporated to enable indirect activation by converting NIR light into UV or visible wavelengths.143 Figure 6Light-responsive vesicles. (a) Schematic illustration of polymersome assembly and NIR-induced permeability conversion. (b) 1H NMR spectra of polymersome before [NIR(-)] and after [NIR(+)] irradiation, with the red dotted box highlighting the disappearance of aromatic proton signals (8.1–7.4 ppm) following cleavage of the 2-nitrobenzyl group. (c) Optical transmittance at 700 nm in PBS over time with and without NIR irradiation. Adapted from (He et al, 2021),142 with permission from ACS Publications (License No. 6255240764808).Image A illustrates polymersome assembly and NIR-induced permeability changes. It shows chemical structures of PNBOC, P(OEGMA-co-EoS) and POPN, which self-assemble into an impermeable vesicle containing AQ4N and PEG-UCNPs. NIR irradiation converts the vesicle to a permeable state via cross-linking, with a reaction releasing CO2. Image B presents H NMR spectra of polymersomes before and after NIR exposure. The red dotted box highlights the disappearance of aromatic proton signals between 8.1 and 7.4 ppm after NIR irradiation. Image C displays a graph of optical transmittance at 700 nm in PBS over time, with the x-axis as Time (minutes) and the y-axis as Transmittance (%). The NIR plus line shows increasing transmittance, while the NIR minus line remains constant.A schematic of light-responsive vesicles with NIR-induced permeability and related data. Light-responsive vesicles. (a) Schematic illustration of polymersome assembly and NIR-induced permeability conversion. (b) 1H NMR spectra of polymersome before [NIR(-)] and after [NIR(+)] irradiation, with the red dotted box highlighting the disappearance of aromatic proton signals (8.1–7.4 ppm) following cleavage of the 2-nitrobenzyl group. (c) Optical transmittance at 700 nm in PBS over time with and without NIR irradiation. Adapted from (He et al, 2021),142 with permission from ACS Publications (License No. 6255240764808). However, light-response systems present several limitations, including poor tissue penetration of UV light, phototoxicity, and potential cytotoxicity byproducts associated with photocleavable moieties.138 Consequently, light-triggered vesicular systems are largely limited to superficial or externally accessible tissues, with vesicle structural properties further constraining design flexibility.44 Magnetic Field An external magnetic field enables site-specific accumulation or localized hyperthermia.144 However, incorporating magnetic responsiveness into liposomes and exosomes remains challenging owing to limited membrane tunability and dependence on predefined lipid components.44 Consequently, magnetic functionality in vesicular systems is most commonly achieved by incorporating superparamagnetic iron oxide nanoparticles (SPIONs). Depending on system design, magnetic actuation may require relatively high field strengths to achieve effective responses.145 As a result, SPION-based strategies are widely used owing to their versatility across liposomal and polymeric carriers.146 However, imparting intrinsic magnetic responsiveness directly to vesicular membranes remains a significant challenge, particularly in lipid-based systems, resulting in relatively limited development of intrinsically magnetic vesicles compared with SPION-assisted systems. Electric Field Electric fields enable controlled drug release from vesicular systems under direct current (DC) stimulation, promoting localized activation with precise temporal control and dosage modulation.147 Electric-field-responsive mechanisms include electroporation, electrochemical redox processes, and membrane destabilization, with electroporation being the most widely utilized in vesicular systems. In this mechanism, transient pore formation under electric pulses increases membrane permeability and facilitates drug release.148 Additionally, electroactive moieties, such as ferrocene, have been incorporated into vesicular membranes to enable redox-mediated responsiveness.102 For example, electro-responsive liposomes incorporating ferrocenyl amphiphiles undergo oxidation of ferrocene to the hydrophilic ferricenium state upon electrical stimulation, destabilizing the membrane and triggering the release of encapsulated carbamazepine.148 Similarly, electroporation enhances both intracellular uptake and drug release from gentamicin-loaded liposomes by transiently increasing membrane permeability.102 Compared with polymersomes, liposomes—owing to their thinner and less mechanically robust membranes—are more susceptible to electric field–induced destabilization.148 However, incorporation of electroactive components, such as polypyrrole or polyaniline, into vesicular carriers remains structurally challenging.149 In addition, the requirement for external stimulation devices may limit translational applicability.147 Consequently, electrically responsive vesicular systems remain less developed compared with other stimulus-responsive platforms.150 Ultrasound Ultrasound is a non-invasive external stimulus characterized by deep tissue penetration and tunable parameters. In ultrasound-responsive systems, drug release is primarily mediated by cavitation and mechanical stress.12,15,27,151 Liposomes and polymersomes have been engineered to respond to ultrasound, with liposomes generally exhibiting greater susceptibility to ultrasound-induced release.151 In contrast, polymersomes exhibit greater mechanical stability but often require the incorporation of ultrasound-sensitive components to achieve comparable responsiveness. For example, ultrasound-triggered liposomes containing DOPE undergo pressure-induced membrane destabilization under acoustic stimulation, resulting in enhanced drug release compared with conventional hydrogenated soy phosphatidylcholine (HSPC)-based liposomes.27 Similarly, ultrasound-responsive polymersomes composed of poly(ethylene oxide)-block-poly(2-(dimethylamino)ethyl methacrylate)-stat-poly(methoxyethyl methacrylate) [PEO-b-p(DEA-stat-MEMA)] demonstrate increased drug release upon ultrasound exposure owing to the acoustic sensitivity of the hydrophobic PMEMA block.106 In addition, ultrasound-responsive cerasomes encapsulating the STING agonist SR-717 generate ROS via porphyrin moieties under ultrasound irradiation, leading to oxidative disruption of the DOPC bilayer and enhanced immunotherapy activity.15 To enhance ultrasound responsiveness, vesicular carriers are often integrated with gas-generating components, such as nanobubbles, microbubbles, and nanodroplets, to amplify cavitation effects.106 Ultrasound-induced thermal effects and ROS generation can also contribute to membrane destabilization and drug release. However, the high acoustic intensities required for direct membrane disruption may cause unintended tissue damage.152 Consequently, most systems rely on auxiliary sensitization strategies rather than ultrasound alone. Heat Thermoresponsive vesicular systems release drugs in response to temperature change, particularly under mild hyperthermia (40–42°C).13 Heat-responsive peptides, such as elastin-like polypeptides, may be incorporated to induce structural transitions.153 Although early approaches sought to exploit intrinsic temperature differences between normal and pathological tissues, such differences are typically insufficient in vivo. Therefore, mild hyperthermia is generally induced externally using high-intensity focused ultrasound, photothermal heating, or other localized heating strategies.154 Liposomes are the most extensively studied vesicular carriers.155 An increase in temperature induces a gel-to-liquid crystalline phase transition in the liposomal bilayer, thereby increasing membrane permeability and triggering drug release.101,156 A commonly used phospholipid in liposomes, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), exhibits a phase transition temperature of approximately 41–42°C.155 Under these conditions, thermosensitive liposomes remain stable at physiological temperature but rapidly release drugs upon exposure to hyperthermic conditions.13,101,104 Thermoresponsive polymersomes, such as poly(N-vinylcaprolactam) (PVCL) and poly(N-isopropylacrylamide) (PNIPAM), which undergo phase transitions above their critical transition temperatures, are commonly employed.155,157 PVCL-based thermosensitive polymersomes exhibit temperature-dependent drug release behavior within the range of 37–41 °C.105 This strategy has also been extended to hybrid vesicular systems; for example, thermosensitive liposome–exosome hybrid nanocarriers enable anticancer drug release under mild hyperthermia conditions.120 In addition to phase transition approaches, thermocleavable linkers, such as azo-based and Diels–Alder linkages, have been explored.158 However, their relatively high cleavage temperature limits applicability under physiological conditions, necessitating chemical modification to reduce activation thresholds.158 Overall, phase transition-based systems are more widely adopted owing to their activation under mild conditions, whereas thermocleavable systems remain limited by their higher activation thresholds. Targeting Strategies and Remaining Challenges Conventional vesicular carriers primarily facilitate drug accumulation through passive targeting; however, their clinical performance is often limited by nonspecific biodistribution and rapid systemic clearance.1,155 Stimuli-responsive systems have been developed to enable on-demand drug release and spatiotemporal control of therapeutic activity, thereby improving delivery precision rather than merely enhancing accumulation. In parallel, active targeting strategies employ specific ligands to promote selective binding to receptors overexpressed at diseased sites, thereby enhancing cellular uptake and therapeutic efficacy (Figure 7). Folate receptors (FR) are commonly upregulated in cancers and inflammatory diseases. Other receptors, including CD44, integrins (eg, αvβ3 and αvβ5), urokinase-type plasminogen activator receptor (uPAR), epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), transferrin receptors, and CXCR4, may also be overexpressed depending on the disease context.1,94,155,159–164 Figure 7Schematic illustration of ligand-mediated active targeting of vesicles. Created with BioRender.com.A schematic of ligand-mediated active targeting of vesicles with targeting moiety and receptor interaction. Schematic illustration of ligand-mediated active targeting of vesicles. Created with BioRender.com. Dual-targeting strategies, which combine two ligands or integrate receptor-targeting ligands with cell-penetrating peptides, further enhance targeting efficiency by promoting both receptor-mediated binding and intracellular internalization.112,165 In addition, subcellular targeting strategies, such as the incorporation of mitochondria-targeting peptides, have been developed to direct vesicles toward specific intracellular organelles.96 These targeting strategies are increasingly integrated with stimuli-responsive systems to achieve precise spatiotemporal control over drug delivery.1,94,164 However, heterogeneity in receptor expression and the complexity of the pathological microenvironment may limit targeting efficiency, highlighting the need for more adaptable and multifunctional delivery platforms.159 Despite advances in both stimuli-responsive and targeting strategies, the efficient delivery of biomacromolecules, particularly proteins, remains challenging owing to their structural instability and limited intracellular availability. Vesicle-Based Artificial Cells: Toward Functional Therapeutic Systems Recently, research has expanded beyond conventional drug delivery toward vesicle-based artificial cells capable of performing complex biological reactions.166 Artificial cells, or synthetic cells, are engineered cell-like constructs that replicate selected functions of living systems.167 The concept of artificial cells was first introduced by Chang in 1957 with the development of semipermeable microcapsule systems for biomimetic applications.168 These platforms are compartmentalized architectures capable of supporting life-like functions, including molecular synthesis, information processing, and signal transduction.23,25,166,167 In addition to membrane-bound vesicular systems, membrane-less coacervate-based compartments have also been explored as artificial cell models owing to their ability to efficiently concentrate biomolecules and facilitate biochemical reactions.169 In drug delivery, artificial cells facilitate the in situ synthesis of therapeutic biomolecules near or within target tissues.170,171 This approach is particularly advantageous for delivering complex biomacromolecules, such as structurally intricate or cytotoxic proteins, which are difficult to produce in living cells, as it enables their on-demand production and delivery to target cells.171,172 Because artificial cells are defined by their ability to mimic specific cellular functions, simple vesicles are not typically classified as artificial cells.167 Among various platforms, giant unilamellar vesicles (GUVs), typically larger than 1 μm, are the most widely used model systems.173 Emulsification and microfluidic approaches are frequently employed to prepare GUVs, as they offer better control over size, encapsulation efficiency, and unilamellarity.23,172,174 These structures can host enzymatic reactions and support protein expression via the transcription–translation machinery.172 In addition to liposomes, polymersomes have garnered attention owing to their enhanced structural stability, although their membrane fluidity is lower than that of natural cell membranes.173,175,176 Other vesicular systems, including proteinosomes, niosomes, and dendrimersomes, have also been investigated as structural platforms.170,173 This section focuses on bottom-up approaches, in which artificial cells are constructed from nonliving components, such as lipids and polymers, to reconstruct selected cellular functions. The following subsections highlight key functional aspects relevant to drug delivery, including in situ biosynthesis, stimuli-responsive autocrine behavior, and cell–cell communication (Figure 8). Figure 8Functional advancement of vesicular nanocarriers toward artificial cell-like systems for next-generation drug delivery. Created with BioRender.com.A scientific infographic titled ′Artificial cell-like system′ features a header and three side-by-side panels. The header shows a nanoparticle, approximately 200 nanometers and an artificial cell, greater than 1 micrometer. The first panel, ′On-site synthesis′, includes a vesicle labeled ′Cell-free protein synthesis CFPS′ with components: ribosome, tRNA, amino acids, ATP and enzyme. The second panel, ′Stimulus-triggered release′, depicts a vesicle with arrows indicating substrates entering and products exiting. The third panel, ′Cell-cell communication′, shows artificial cells interacting with living cells, with arrows suggesting communication. Each panel is boxed, emphasizing the processes involved in artificial cell systems.Three-panel infographic on artificial cell systems: synthesis, release, communication. Functional advancement of vesicular nanocarriers toward artificial cell-like systems for next-generation drug delivery. Created with BioRender.com. In situ Therapeutic Synthesis Artificial cells replicate the ability to synthesize biomolecules within confined compartments.176 Vesicular systems must support membrane permeability and intravesicular reactions, allowing externally supplied molecules to enter, react within the vesicle, and subsequently diffuse out.171,173 For example, an approximately 66 kDa Pseudomonas exotoxin A (PEA) was synthesized inside liposomes using a cell-free protein synthesis (CFPS) system (Figure 9a). Protein expression within the vesicles was confirmed by Western blot and confocal laser scanning microscopy (CLSM), and the system produced various proteins by altering the DNA template (Figure 9b). When these vesicles were applied to 4T1 cells, the internally synthesized PEA induced substantial cytotoxicity. In vivo tumor immunofluorescence further confirmed protein production and release within the tumor microenvironment, highlighting the therapeutic potential of in situ protein synthesis in artificial cells (Figure 9c).171 In another study, artificial cells were shown to support multistep metabolic pathways, including de novo nucleotide synthesis followed by RNA transcription within vesicular compartments. These findings underscore the potential of artificial cells to locally synthesize therapeutic RNA near tumor sites, which can be translated into proteins and mediate therapeutic effects.25 Collectively, these studies demonstrate that vesicle-based artificial cells can function as synthetic nanoreactors, enabling the localized production of therapeutic biomolecules. Figure 9(a) Schematic illustration of the transport of molecular building blocks required for transcription and translation across the vesicle membrane. (b) Protein production inside liposomal particles was demonstrated using green fluorescent protein (GFP) as a model. (c) Tissue sections were analyzed for the presence of the apoptotic marker caspase-3 and proteins produced within the particles. Nuclei are shown in blue (4′,6-diamidino-2-phenylindole, DAPI), caspase-3 expression in red, and protein expression in green. GFP was used as a surrogate marker for PEA levels, enabling visualization of particle biodistribution in vivo. Adapted from (Krinsky et al, 2018)171 with permission from Wiley (License No. 6255241002052).Image showing molecular transport across the vesicle membrane, protein production inside liposomes, and caspase 3 & GFP expression in tissue sections. (a) Schematic illustration of the transport of molecular building blocks required for transcription and translation across the vesicle membrane. (b) Protein production inside liposomal particles was demonstrated using green fluorescent protein (GFP) as a model. (c) Tissue sections were analyzed for the presence of the apoptotic marker caspase-3 and proteins produced within the particles. Nuclei are shown in blue (4′,6-diamidino-2-phenylindole, DAPI), caspase-3 expression in red, and protein expression in green. GFP was used as a surrogate marker for PEA levels, enabling visualization of particle biodistribution in vivo. Adapted from (Krinsky et al, 2018)171 with permission from Wiley (License No. 6255241002052). Stimulus-Regulated Biochemical Functions In these systems, external stimuli regulate membrane permeability or activate encapsulated reactions, enabling controlled production or release of therapeutic molecules. For example, glucose-responsive liposome-based artificial cells have been developed by incorporating glucose transporter 2 (GLUT2) into the vesicle membrane. Under hyperglycemic conditions, glucose is transported into the vesicle lumen via GLUT2 and subsequently oxidized by an encapsulated glucose-metabolizing system, thereby decreasing the internal pH. This pH change induces membrane fusion between an inner insulin-containing liposome and the outer membrane through interactions between complementary peptides, resulting in the release of insulin into the surrounding environment.177 In another approach, β-galactosidase (β-gal) was encapsulated within an oxidation-responsive polymersome, while the substrate was supplied externally. Upon exposure to hydrogen peroxide (H2O2), the polymersome membrane exhibited increased permeability, allowing the substrate 4-methylumbelliferyl-β-D-galactopyranoside (4-MUG) to diffuse into the lumen. Inside the vesicle, 4-MUG was hydrolyzed by β-gal to generate the fluorescent product 4-methylumbelliferone (4-MUB), confirming that enzymatic reactions occurred within the confined compartment.176 In addition to direct chemical responsiveness, artificial cells can be engineered to regulate cargo release through gene expression (Figure 10a). Thermo-responsive synthetic cells utilize an mRNA-based temperature-sensing system, in which an RNA thermometer activates the expression of the pore-forming protein α-hemolysin (αHL) upon temperature stimulation (Figure 10b). The expressed αHL inserts into the membrane to form pores, allowing passive diffusion of small molecules from the vesicle (Figure 10c).174 Figure 10Artificial cells as enzyme-encapsulated nanoreactors. (a) Schematic illustration of synthetic cells containing a cell-free protein expression (CFPE) system with RNA thermometers (RNATs), enabling temperature-regulated protein expression and membrane insertion of pore-forming proteins. (b) Temperature-responsive systems in which heat activation induces the expression of αHL, leading to pore formation in the membrane and subsequent cargo release. (c) Time-dependent release of fluorescent cargo (calcein) from synthetic cells upon temperature stimulation, as evidenced by the decrease in fluorescence intensity (Scale bars: 20 μm). Adapted from (Monck et al, 2024)174, Springer Nature, distributed under the Creative Commons Attribution (CC BY 4.0) license.The image shows a schematic illustration of synthetic cells containing a cell-free protein expression system with RNA thermometers. In section (a), DNA is transcribed to mRNA, which is then translated into protein, illustrating cell-free protein synthesis. RNA thermometers regulate translation by reversible denaturation of mRNA secondary structure. The synthetic cell is depicted with a lipid membrane and α-hemolysin synthesized in situ. Section (b) describes the process of heat induction leading to α-hemolysin synthesis, membrane insertion and cargo release. Section (c) shows fluorescence images before and after temperature stimulation, with a graph showing increased cargo release at 42 degrees Celsius compared with 30 degrees Celsius.Schematic of synthetic cells with RNA thermometers for temperature-regulated protein expression and cargo release. Artificial cells as enzyme-encapsulated nanoreactors. (a) Schematic illustration of synthetic cells containing a cell-free protein expression (CFPE) system with RNA thermometers (RNATs), enabling temperature-regulated protein expression and membrane insertion of pore-forming proteins. (b) Temperature-responsive systems in which heat activation induces the expression of αHL, leading to pore formation in the membrane and subsequent cargo release. (c) Time-dependent release of fluorescent cargo (calcein) from synthetic cells upon temperature stimulation, as evidenced by the decrease in fluorescence intensity (Scale bars: 20 μm). Adapted from (Monck et al, 2024)174, Springer Nature, distributed under the Creative Commons Attribution (CC BY 4.0) license. Vesicle–Cell Communication Interactive Systems Artificial cells can synthesize therapeutic proteins or response molecules upon external stimulation, whereas living cells regulate physiological processes by secreting signaling molecules, such as neurotransmitters.166 Consequently, intercellular communication represents a critical function of artificial cells. Recent research has expanded this concept to communication networks involving both artificial and natural cells. For example, artificial cells have been developed to interact with mammalian neurons and promote neural stem cell differentiation (Figure 11a).166 These systems are equipped with DNA templates encoding transcription–translation machinery, brain-derived neurotrophic factor (BDNF), LuxR, and perfringolysin O (PFO). In response to the signaling molecule N-(3-oxohexanoyl)-homoserine lactone (3OC6 HSL), the quorum-sensing regulator LuxR induces expression of PFO, which forms membrane pores and facilitates the release of constitutively produced BDNF. The released BDNF activates tropomyosin receptor kinase B (TrkB) signaling in neural stem cells, promoting neuronal differentiation and maturation (Figure 11b). Prolonged culture with mouse embryonic stem cell–derived neural stem cells resulted in successful neuronal differentiation (Figure 11c), and a BDNF-responsive human embryonic kidney 293T (HEK293T) reporter system further confirmed the activation of downstream signaling pathways (Figures 11d–e). Notably, artificial cells have demonstrated the ability to interact with living cells by producing and releasing signaling molecules that modulate cellular behavior, such as inducing stem cell differentiation via receptor-mediated pathways. These findings highlight their potential as interactive therapeutic platforms capable of sensing and actively influencing biological environments. Figure 11Chemical communication between artificial and mammalian cells. (a) Communication between artificial cells and neural stem cells. Expression of the pore-forming protein PFO is regulated by a genetic AND gate requiring LuxR and 3OC6 HSL. The resulting membrane pores facilitate the release of BDNF, which activates TrkB signaling pathways, thereby promoting neural differentiation. (b) Schematic overview of artificial cell treatment and neural stem cell differentiation. (c) Immunofluorescence images showing differentiation of mouse neural stem cells (mNS) into mature neurons after 19 days (scale bars: 50 μm). (d) Representative images of GFP expression in engineered HEK293T cells (scale bars: 50 μm). (e) Quantitative analysis of GFP-expressing HEK293T cells following treatment with artificial cells. Adapted from (Toparlak et al, 2020)166, American Association for the Advancement of Science, distributed under the Creative Commons Attribution (CC BY 4.0) license.The image A shows chemical communication between artificial cells and mammalian cells. It illustrates the expression of PFO regulated by LuxR and 3OC6 HSL, leading to pore formation and BDNF release, promoting neural differentiation. The image B depicts the signaling pathway where BDNF activates TrkB, leading to CREB activation and differentiation factor release. The image C presents immunofluorescence images showing differentiation of mouse neural stem cells into mature neurons, with Hoechst, βIII-Tubulin, MAP2 and merged views under different conditions: Background, BDNF minus 3OC6 HSL and BDNF plus 3OC6 HSL. The image D shows GFP expression in HEK293T cells under similar conditions. The image E is a bar graph showing the percentage of GFP positive cells compared to the background, with a significant increase in BDNF plus 3OC6 HSL condition (P equals 0.0144).A composite image showing chemical communication and differentiation in artificial and mammalian cells. Chemical communication between artificial and mammalian cells. (a) Communication between artificial cells and neural stem cells. Expression of the pore-forming protein PFO is regulated by a genetic AND gate requiring LuxR and 3OC6 HSL. The resulting membrane pores facilitate the release of BDNF, which activates TrkB signaling pathways, thereby promoting neural differentiation. (b) Schematic overview of artificial cell treatment and neural stem cell differentiation. (c) Immunofluorescence images showing differentiation of mouse neural stem cells (mNS) into mature neurons after 19 days (scale bars: 50 μm). (d) Representative images of GFP expression in engineered HEK293T cells (scale bars: 50 μm). (e) Quantitative analysis of GFP-expressing HEK293T cells following treatment with artificial cells. Adapted from (Toparlak et al, 2020)166, American Association for the Advancement of Science, distributed under the Creative Commons Attribution (CC BY 4.0) license. Beyond interactions with living systems, artificial cells have been engineered to communicate with one another. Antagonistic sender–receiver systems have been developed using liposome-based GUVs. The sender vesicles encapsulate urease and acetylcholinesterase (AChE), while the receiver vesicles contain a pH-responsive DNA nanostructure. When urea enters the sender vesicle, urease catalyzes its conversion into ammonia, which diffuses across the membrane, increasing the pH within the receiver vesicle and triggering a conformational transition of the DNA nanostructure from a triplex to a duplex. Conversely, the introduction of acetylcholine results in the generation of acetic acid by AChE, which diffuses into the receiver vesicle, lowering the pH and inducing a reverse structural transition. These results demonstrate that chemically generated signals can be transmitted between artificial cells to regulate internal processes, highlighting the feasibility of artificial cell–artificial cell communication.178 These systems illustrate the potential for constructing synthetic communication networks. Despite these advancements, clinical translation remains hindered by some limitations. These include the need to balance membrane stability with selective permeability to facilitate controlled molecular exchange under physiological conditions;173 sustaining long-term functionality due to substrate depletion and energy limitations in CFPS systems;179 and overcoming the large size of artificial cell platforms such as GUVs, which results in rapid clearance and limited tissue penetration in vivo.180 To overcome these limitations, recent efforts have focused on membrane engineering and the development of multicompartment architectures, such as vesicle-in-vesicle systems, to enable more complex and sustained biochemical processes.23,167 Looking forward, integrating sensing, synthesis, and communication into a single platform will be essential. Advances in materials science and synthetic biology are expected to drive the development of more adaptive artificial cells, facilitating their translation into next-generation therapeutic systems.173 Conclusion This review highlights the functional evolution of vesicular systems from conventional drug delivery carriers to stimuli-responsive platforms and, ultimately, to artificial cell-like systems. While early vesicular nanocarriers primarily served as passive reservoirs for therapeutic cargos, advances in membrane engineering, functional materials, and stimuli-responsive design have progressively transformed them into active therapeutic systems capable of controlled drug release, environmental sensing, and biological interactions. More recently, the emergence of artificial cell-like vesicles has expanded the role of vesicular platforms beyond drug delivery by enabling in situ biosynthesis, signal-mediated communication, and cell-mimetic functions. Collectively, these developments illustrate a paradigm shift in vesicle research—from improving cargo delivery efficiency to engineering adaptive therapeutic systems that actively participate in disease treatment. Despite substantial progress, challenges remain in achieving precise control over membrane stability and permeability, integrating multiple biological functions within a single platform, and ensuring robust performance under physiological conditions. In addition, successful translation of advanced vesicular systems will require careful optimization and evaluation of critical quality attributes, including particle size, size distribution, encapsulation efficiency, and stability. Future advances at the interface of nanomedicine, materials science, and synthetic biology are expected to accelerate the development of multifunctional vesicular systems with increasing autonomy and biological complexity. In addition, emerging artificial intelligence- and machine learning-based approaches may further facilitate the rational design and optimization of vesicular platforms by enabling efficient formulation screening, prediction of physicochemical properties, and identification of optimal therapeutic strategies. Ultimately, vesicle-based artificial cells may provide a foundation for next-generation therapeutic platforms capable of sensing, responding to, and modulating biological environments in ways that conventional drug delivery systems cannot fully achieve.